The dihydrofolate reductase (fol) gene in Escherichia coli has been deleted and replaced by a selectable marker. Verification of the Afol::kan strain has been accomplished using genetic and biochemical criteria, including Southern analysis of the chromosomal DNA. The Afol::kan mutation is stable in E. coli K549 [thyA poUA12 (Ts) Genetic studies of the DHFR (fol) locus in Escherichia coli have typically described mutations which increase DHFR protein production or decrease inhibitor binding to DHFR, or both (9, 26, 27, 30, 31) . No temperature-sensitive mutations in the fol gene have been reported, and only recently has one DHFR-deficient strain been isolated (29). The DHFR-deficient strain is apparently devoid of DHFR activity, and it requires the presence of Fol end products (thymine, adenine, glycine, methionine, pantothenate) for growth. The lesion (a likely point mutation) is uncharacterized and could be in the DHFR coding sequence or in a control region.
The dihydrofolate reductase (fol) gene in Escherichia coli has been deleted and replaced by a selectable marker. Verification of the Afol::kan strain has been accomplished using genetic and biochemical criteria, including Southern analysis of the chromosomal DNA. The Afol::kan mutation is stable in E. coli K549 [thyA poUA12 (Ts)] and can be successfully transduced to other E. coli strains providing they have mutations in their thymidylate synthetase (thyA) genes. A preliminary investigation of the relationship betweenfol and thyA gene expression suggests that a Fol-cell (i.e., a dihydrofolate reductase deficiency phenotype) is not viable unless thymidylate synthetase activity is concurrently eliminated. This observation indicates that either the nonproductive accumulation of dihydrofolate or the depletion of tetrahydrofolate cofactor pools is lethal in a FolThyA+ strain. Strains containing the thyA Afol::kan lesions require the presence of Fol end products for growth, and these lesions typically increase the doubling time of the strain by a factor of 2.5 in rich medium.
Dihydrofolate reductase (DHFR; EC 1.5.1.3) catalyzes the reduction of dihydrofolate to tetrahydrofolate with the concurrent oxidation of NADPH to NADP+. This activity is necessary in maintaining intracellular pools of tetrahydrofolate cofactors which are essential for biosynthetic reactions involving the transfer of one-carbon units. Inhibition of DHFR activity initially results in depletion of N5,N'0-methylene tetrahydrofolate, followed by inhibition of DNA synthesis and ultimately cell death. Antifolate drugs which have DHFR as their target include trimethoprim (antibacterial), methotrexate (anticancer), and pyrimethamine (antimalarial).
Genetic studies of the DHFR (fol) locus in Escherichia coli have typically described mutations which increase DHFR protein production or decrease inhibitor binding to DHFR, or both (9, 26, 27, 30, 31) . No temperature-sensitive mutations in the fol gene have been reported, and only recently has one DHFR-deficient strain been isolated (29) . The DHFR-deficient strain is apparently devoid of DHFR activity, and it requires the presence of Fol end products (thymine, adenine, glycine, methionine, pantothenate) for growth. The lesion (a likely point mutation) is uncharacterized and could be in the DHFR coding sequence or in a control region.
Our interest in a true fol strain arose from needing to express mutant E. coli DHFR genes in a Fol-(DHFRdeficient) background. Our mutant DHFR genes are obtained by site-directed mutagenesis techniques and are cloned in multicopy plasmids (14, 34) . While expression of the chromosomal gene typically results in <1% contamination of the purified mutant protein by wild-type DHFR, this level of contamination can cause significant kinetic effects when the mutant DHFR activity is low (14) . Therefore, to express our mutant DHFR genes and minimize any possible recombination between chromosomal and plasmid E. coli DHFR genes, we have deleted the DHFR gene from the E. coli chromosome and studied the effects of this null allele on strain viability. The relationship between expression of DHFR and thymidylate synthetase activities was additionally investigated when we found our 4fol::kan mutation was not viable in a ThyA+ background.
MATERIALS AND METHODS
Bacteria and plasmids. The E. coli (K-12) strains and plasmids used in this research are listed in Table 1 . P1 vir was the generous gift of Doug Smith (University of California, San Diego), and plasmids pAGts and M14) were the gifts of Ernest Villafranca (Agouron Pharmaceuticals, Inc.) and Chris Morris (California Institute of Technology), respectively. pBR328 and pUC4K were obtained from BoehringerMannheim and Pharmacia, respectively.
To grow E. coli thyA Afol::kan strains on Bonner-Vogel minimal plates (35) it was necessary to supplement the medium with thymine (200 p.g/ml), adenine (20 p.g/ml), pantothenate (1 ,ug/ml), and glycine and methionine (50 ,ug/ml each) (29) . Any E. coli thyA strains grown on Bonner-Vogel minimal plates were supplemented with 200 ,ug of thymine per ml. Cells were typically grown in L broth. When required, trimethoprim, kanamycin, ampicillin, and chloramphenicol were added at concentrations of 10 to 20, 25 to 50, 100 to 200, and 30 ,ug/ml, respectively.
Strain manipulations. Deletion of the DHFR gene was performed as described by Russel and Model (25) Protein analysis. Purification of DHFR followed a standard procedure in which cellular lysates were passed over a methotrexate affinity column (2). High-salt and higb-pH rinses were followed by elution of DHFR with 1 mM folate-1 M KCl-10 mM EDTA-10 mM P-mercaptoethanol in 0.2 M sodium borate buffer (pH 9.0). Salt and folate were subsequently removed by dialysis. DHFR activity was monitored by spectrophotometric assays (14) . Activity stains of cellular lysates run on nondenaturing electrophoretic gels were also used to evaluate the level of DHFR activity (13) .
RESULTS AND DISCUSSION Vector construction. The vector used to delete the E. coli chromosomal DHFR gene was designed (i) to have a large DNA insert so that recombination between vector and chromosome would readily occur, (ii) to concurrently insert a selectable marker (kanamycin resistance) upon deletion of the chromosomal gene for DHFR, and (iii) to utilize a system [e.g., ColEl plasmid in a polA(Ts) E. coli strain] such that plasmid integration and segregation into the chromosome could be easily selected (11, 25) . The first step in constructing a vector for DHFR gene deletion involved cloning the 8.3-kilobase (kb) BamHI fragment containing the -0.5-kb E. coli DHFR structural gene (methionine start point to TAA stop) from pCV29 (31) into pACYC177 (6) . The resulting plasmid was designated pLMF20 and it conferred resistance to trimethoprim, ampicillin, and kanamycin. The kanamycin resistance gene of pLMF20, associated with the pACYC portion of the plasmid, was then inactivated by a unique HindIII cut, followed by BAL 31 nuclease digestion and blunt-end ligation. This plasmid, pLMF21, conferred only trimethoprim and ampicillin resistance. Next, a 1.5-kb Sall fragment encoding the kanamycin resistance gene from pUC4K (23) transcription (i.e., towards the PstI site noted at the top of Fig. 1) .
To delete the DHFR gene from the BamHI fragment, the pLMF22-3 plasmid was cut at the unique EcoRI site in the DHFR-coding sequence, and the DNA was digested with BAL 31 for 10 min. After blunt-end ligation and transformation of the DNA, kanamycin-resistant colonies were obtained and screened for trimethoprim sensitivity. One plasmid conferring these properties (pLMF22-3 B-4) was analyzed by restriction enzyme mapping to determine the size of the deletion. Approximately 1.2 kb was found to be deleted from the BamHI fragment by the BAL 31 digestion. As determined by restriction enzyme mapping, the HincII (promoter region) and PstI (approximately 540 base pairs after the end of the DHFR gene) sites were both lost (see top of Fig. 1) . However, the SalI site on the 3' end of the kanamycin resistance gene was still present. Clearly, the entire DHFR structural gene and its promoter sequence were deleted from the plasmid vector. Note that insertion of a 1.5-kb kanamycin resistance fragment and deletion of 1.2 kb around the DHFR gene slightly increased the BamHI fragment size to 8.6 kb.
Gene deletion. Since our selection procedure for the gene deletion process relies on the replication of ColEl plasmids in temperature-sensitive polA strains (11, 25) , the BamHI fragmnent from pLMF22-3 B-4 was cloned into the ColEl vector pBR328. This vector was named pLH30-2 and it conferred kanamycin, chloramphenicol, and ampicillin resistances on the host cell.
Transformation of pLH30-2 into E. coli K549 poIA12(Ts) allows expression of the ColEl replicon by host DNA polymerase A at permissive temperatures (.30'C) (21) . At restrictive temperatures (.370C), growth only occurs when the plasmid integrates into the chromosome (11, 25) . When K549 cells transformed with pLH30-2 were grown at 42°C, the number of kanamycin and chloramphenicol-resistant colonies obtained was decreased 50-fold as compared with 30°C growth. Those colonies that grew at 42°C were presumed to have the plasmid integrated in the bacterial chromosome at the DHFR gene locus (fol maps at 1 min [3]). Integration of plasmids into the chromosome is proposed to occur by homologous recombination (primarily from a single cross-over event between the vector and the DHFR chromosomal gene) which produces a nontandem duplication separated by the plasmid DNA (11).
Subsequent growth of the strain (containing the presumed integrated plasmid) at 30°C allows the plasmids to segregate from the chromosome. Segregation of a nontandem duplication from the chromosome will result , deletion of either the plasmid DNA containing the chromouomal DHFR gene or the plasmid DNA containing the kanamycin resistance fragment (11, 25) . Loss of the latter would restore the cell to its original genotype, whereas loss of the former would delete the DHFR chromosomal gene. result suggested that the Afol::kan construction was stable in K549 because of a possible suppressor mutation in this strain. An example of compensatory mutations in a second gene is the rescue of DNA topoisomerase I (Atop) mutant cells by mutations in either of the DNA gyrase genes (gyrA, gyrB) (7). The increased growth rates associated with the double-mutant cells suggest that a balance of the topoisomerase and gyrase activities is necessary for cell viability.
One possible suppressor in our K549 Afol::kan strain was the thyA lesion, as thymidylate synthetase (thyA), dihydrofolate reductase, and serine hydroxymethyltransferase compose a three-enzyme cycle (Fig. 3) in pyrimidine metabolism, and it has been shown that inhibition of intracellular DHFR activity decreases or abolishes expression of thymidylate synthetase (15, 22) . When DHFR activity is low or eliminated and thymidylate synthetase activity is unaffected, the intracellular concentration of dihydrofolate will increase and the N5,Nl0-methylene tetrahydrofolate pool will be depleted. Depletion of the N5,N10-methylene tetrahydrofolate pool negatively affects one-carbon biosynthetic pathway reactions. In this situation, a concurrent decrease or loss in thymidylate synthetase activity would allow the N5,N10-methylene tetrahydrofolate pool to be maintained (15) . This connection between DHFR and thymidylate synthetase activities may explain our inability to transduce the Afol::kan mutation into ThyA+ strains.
Another possible interpretation of our inability to trans- Screening of the NM522 thyA Afol::kan strains to confirm their Fol-phenotype included DHFR activity stains of cellular lysates run on nondenaturing electrophoretic gels (13) . No DHFR activity was observed for the cellular lysates from the Afol::kan strains, whereas activity was noted for the NM522 thyA strain. Additionally, these /fol::kan strains grew on Bonner-Vogel medium supplemented with thymine, glycine, pantothenate, methionine, and adenine, but did not grow on nonsupplemented medium (29) . This result illustrates Fol end product auxotrophy. As expected, the Afcl::kan strains could be rescued from Fol end product auxotrophy by transforming them with a plasmid carrying either the E. coli DHFR gene (pAglOl; E. coli DHFR gene carried on a 1.1-kb fragment) (34) or the nonhomologous R-plasmid-encoded R67 DHFR (P700) (5) . The ability of the R67 DHFR to rescue strain LH18 from Fol end product auxotrophy indicates that only the DHFR activity is necessary for cell viability. Any possible requirement for a specific protein structure is eliminated, as the E. coli DHFR sequence and structure are totally different from those of the R67 DHFR (5, 17, 24 
